AI Summary
This article discusses a study supporting the idea that starting treatment with the more potent drug, ofatumumab, early on in multiple sclerosis patients can reduce the risk of long-term disability accumulation. This suggests that early initiation of treatment with ofatumumab may be more beneficial than switching to it later on.
The likelihood of long-term accumulation of disability in patients with multiple sclerosis is significantly lower if the more potent drug is started first.
MDedge News